Premium
Phase I study of fotemustine in pediatric patients with refractory brain tumors
Author(s) -
Hargrave Darren R.,
Bouffet Eric,
Gammon Janet,
Tariq Nauman,
Grant Ron M.,
Baruchel Sylvain
Publication year - 2002
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10814
Subject(s) - medicine , lomustine , carmustine , nitrosourea , neutropenia , medulloblastoma , toxicity , phases of clinical research , chemotherapy , ependymoma , population , refractory (planetary science) , gastroenterology , oncology , surgery , pathology , cyclophosphamide , vincristine , environmental health , physics , astrobiology
BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. METHODS Patients younger than 21 with recurrent/resistant brain tumors were enrolled in a conventional Phase I study. Fotemustine was administered intravenously every 3 weeks at increasing dose levels starting at 100 mg/m 2 . Toxicity and response data were monitored closely. RESULTS Fifteen evaluable patients entered the study and received a total of 45 courses of fotemustine (dose range, 100–175 mg/m 2 ). Myelosuppression was observed, with the dose‐limiting toxicity being Grade 4 neutropenia and thrombocytopenia. Toxicity was delayed and cumulative. The maximum tolerated dose was 150 mg/m 2 every 3 weeks. There were three documented radiologic responses (20% of patients) comprising one partial response and two minor responses in patients with a sarcoma, medulloblastoma, and ependymoma, respectively. CONCLUSIONS Fotemustine administered at a dose of 150 mg/m 2 every 3 weeks is well tolerated in children and has antitumor activity in several brain tumors. This is the first dedicated Phase I study of a single agent nitrosourea in a pediatric population. More comparative studies should be undertaken to define the optimum nitrosourea analog for use in children with brain tumors. Cancer 2002;95:1294–301. © 2002 American Cancer Society. DOI 10.1002/cncr.10814